Editas Medicine, Inc.
NASDAQ:EDIT
3.31 (USD) • At close October 17, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Editas Medicine, Inc. |
Symbool | EDIT |
Munteenheid | USD |
Prijs | 3.31 |
Beurswaarde | 272,996,884 |
Dividendpercentage | 0% |
52-weken bereik | 2.91 - 11.69 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Gilmore O'Neill |
Website | https://www.editasmedicine.com |
An error occurred while fetching data.
Over Editas Medicine, Inc.
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)